|
 |
|
|||||||
|
|||||||||
Copyright © ERS Journals Ltd 1994
Original Articles |
Theophylline in the management of asthma: time for reappraisal?
Theophylline has been used for several decades in the treatment of asthma and remains the most widely prescribed anti-asthma drug worldwide, although the development of newer anti-asthma medications, especially inhaled steroids, has resulted in declining use of theophylline in industrialized countries. Theophylline is now considered to be a bronchodilator, but it is increasingly recognized that theophylline has other anti-asthma activities, which may be more important. Theophylline, even at low plasma concentrations, inhibits the late asthmatic reaction following allergen challenge. These clinical pharmacological observations are substantiated by experimental animal and in vitro data showing that theophylline has several anti-inflammatory activities relevant to asthma. These include the inhibition of cytokine synthesis and release, the inhibition of inflammatory cell activation and microvascular leakage, and the prevention of airway hyperresponsiveness induced by airway inflammation. Theophylline appears to have immunomodulatory effects, even at relatively low plasma concentrations. Based on these considerations, theophylline can be regarded as a useful alternative to other anti-inflammatory drugs for the chronic treatment of mild to moderate asthma. Theophylline should be used at lower doses to achieve plasma concentrations of 5-10 mg.l-1, which will avoid the risk of side-effects. Further studies are required to evaluate the role of low-dose theophylline as an adjunct to low-dose inhaled steroids in the management of chronic asthma. It may now be appropriate to re-evaluate the role of theophylline in asthma management.
This article has been cited by other articles:
|
|
 |
|
  B. M. RuDusky Aminophylline: Exploring Cardiovascular Benefits Versus Medical Malcontent Angiology, May 1, 2005; 56(3): 295 - 304. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Sakai, M. Oike, M. Hirakawa, and Y. Ito Theophylline and cAMP inhibit lysophosphatidic acid-induced hyperresponsiveness of bovine tracheal smooth muscle cells J. Physiol., May 15, 2003; 549(1): 171 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes Theophylline: New Perspectives for an Old Drug Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 813 - 818. [Full Text] [PDF]
|
|
|
|
 |
|
 P A Beckett and P H Howarth Pharmacotherapy and airway remodelling in asthma? Thorax, February 1, 2003; 58(2): 163 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-O. Carlsson, R. Olsson, O. Kallskog, B. Bodin, A. Andersson, and L. Jansson Glucose-induced islet blood flow increase in rats: interaction between nervous and metabolic mediators Am J Physiol Endocrinol Metab, September 1, 2002; 283(3): E457 - E464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ito, S. Lim, G. Caramori, B. Cosio, K. F. Chung, I. M. Adcock, and P. J. Barnes A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression PNAS, June 25, 2002; 99(13): 8921 - 8926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Kramer, J. Preuner, A. Ebenburger, M. Kaiser, U. Bergner, C. Eilles, M. C. Kammerl, G. A. J. Riegger, and D. E. Birnbaum Lack of renoprotective effect of theophylline during aortocoronary bypass surgery Nephrol. Dial. Transplant., May 1, 2002; 17(5): 910 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhong, J. L. Chunn, J. B. Volmer, J. R. Fozard, and M. R. Blackburn Adenosine-Mediated Mast Cell Degranulation in Adenosine Deaminase-Deficient Mice J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 433 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.P. Hart Should aminophylline be abandoned in the treatment of acute asthma in adults? QJM, November 1, 2000; 93(11): 761 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yasui, K. Agematsu, K. Shinozaki, S. Hokibara, H. Nagumo, S. Yamada, N. Kobayashi, and A. Komiyama Effects of theophylline on human eosinophil functions: comparative study with neutrophil functions J. Leukoc. Biol., August 1, 2000; 68(2): 194 - 200. [Abstract] [Full Text]
|
|
|
|
 |
|
 Adjuvant therapy Can. Med. Assoc. J., November 1, 1999; 161(90111): s35 - 39. [Full Text]
|
|
|
|
 |
|
 L. Wiegand, C. N. Mende, G. Zaidel, C. W. Zwillich, V. J. Petrocella, S. W. Yancey, and K. A. Rickard Salmeterol vs Theophylline: Sleep and Efficacy Outcomes in Patients With Nocturnal Asthma Chest, June 1, 1999; 115(6): 1525 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Aoki, G. Zhao, D. Qiu, L. Shi, and P. N. Kao CsA-sensitive purine-box transcriptional regulator in bronchial epithelial cells contains NF45, NF90, and Ku Am J Physiol Lung Cell Mol Physiol, December 1, 1998; 275(6): L1164 - L1172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. CHEUNG, A. M. J. WEVER, J. A. de GOEIJ, C. S. de GRAAFF, H. STEEN, and P. J. STERK Effects of Theophylline on Tolerance to the Bronchoprotective Actions of Salmeterol in Asthmatics In Vivo Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 792 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Evans, D. A. Taylor, O. Zetterstrom, K. F. Chung, B. J. O'Connor, and P. J. Barnes A Comparison of Low-Dose Inhaled Budesonide plus Theophylline and High-Dose Inhaled Budesonide for Moderate Asthma N. Engl. J. Med., November 13, 1997; 337(20): 1412 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Weinberger and L. Hendeles Theophylline in Asthma N. Engl. J. Med., May 23, 1996; 334(21): 1380 - 1388. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |